• Traverse
    • Timmerman Traverse for LSC 2025
    • Past Climbs (2018-2025)
  • Speaking
  • About
    • Community
    • Frontpoints
    • Podcast
    • Events
    • Advisors
    • Team
      • David Shaywitz
      • Alex Harding
      • Pedro Rafael Rosado
      • Steve White
    • Hood Biography
    • In the News
    • Testimonials
  • Contact
  • Subscribe
    • Individual Subscriptions
    • Group Subscriptions
Biotech Leaders Get It
  • Traverse
    • Timmerman Traverse for LSC 2025
    • Past Climbs (2018-2025)
  • Speaking
  • About
    • Community
    • Frontpoints
    • Podcast
    • Events
    • Advisors
    • Team
      • David Shaywitz
      • Alex Harding
      • Pedro Rafael Rosado
      • Steve White
    • Hood Biography
    • In the News
    • Testimonials
  • Contact
  • Subscribe
    • Individual Subscriptions
    • Group Subscriptions
12
Jan
2017

Brace Yourselves, Pharma – Trump’s Coming After You

/
Leora Schiff
/
2
/
All, Politics
12 Jan 2017

Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more.

 
Subscribe Now
 
Sign in to your account.
9
Jan
2017

It’s Time for Biopharma to Promote Public Health

/
Kyle Serikawa
/
0
/
All, Politics
09 Jan 2017

Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more.

 
Subscribe Now
 
Sign in to your account.
6
Jan
2017

Amgen Wins PCSK9 Duel, Jenkins’ Parting Shot, and Obamacare’s Last Stand

/
Luke Timmerman
/
0
/
All
06 Jan 2017

Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more.

 
Subscribe Now
 
Sign in to your account.
5
Jan
2017

Neon Therapeutics Gets $70M to Push Neoantigen Cancer Vaccines

/
Luke Timmerman
/
4
/
All, Cancer, Drugs, Venture Capital
05 Jan 2017

Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more.

 
Subscribe Now
 
Sign in to your account.
30
Dec
2016

Big RNA Day For Spinraza, Cempra Stumbles, and Intarcia Rakes in More Loot

/
Luke Timmerman
/
0
/
All
30 Dec 2016

Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more.

 
Subscribe Now
 
Sign in to your account.
23
Dec
2016

Senators Dial Up the Heat, the Overblown CRISPR Case, & Biogen’s New CEO

/
Luke Timmerman
/
0
/
All
23 Dec 2016

Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more.

 
Subscribe Now
 
Sign in to your account.
22
Dec
2016

Unfashionable Science, and a Daring Model for Alzheimer’s, Without VCs

/
Luke Timmerman
/
1
/
All, People, Science
22 Dec 2016

Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more.

 
Subscribe Now
 
Sign in to your account.
16
Dec
2016

Merck Thumps Gilead in Court, Genentech’s New CEO, Alexion Turmoil

/
Luke Timmerman
/
0
/
All
16 Dec 2016

Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more.

 
Subscribe Now
 
Sign in to your account.
9
Dec
2016

Trump Vows Drug Price Clampdown, A Wackadoodle FDA Boss, & Alzheimer’s Heat

/
Luke Timmerman
/
1
/
All, Politics
09 Dec 2016

Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more.

 
Subscribe Now
 
Sign in to your account.
8
Dec
2016

13 Young People Bucking the Odds, Finding Paths to Break Into Biotech 

/
Luke Timmerman
/
1
/
All, People
08 Dec 2016

Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more.

 
Subscribe Now
 
Sign in to your account.
6
Dec
2016

Tom Price’s Doctor-Centered Approach to Healthcare

/
Leora Schiff
/
2
/
All, Politics
06 Dec 2016

Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more.

 
Subscribe Now
 
Sign in to your account.
2
Dec
2016

21st Century Cures Rolls Thru House, Price Poised to Gut Obamacare, and Bluebird Soars

/
Luke Timmerman
/
0
/
All, Politics
02 Dec 2016

Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more.

 
Subscribe Now
 
Sign in to your account.
30
Nov
2016

Pursuing Autism Through the Gut-Brain Axis, Startup Axial Raises $19M

/
Luke Timmerman
/
2
/
All, Science, Venture Capital
30 Nov 2016

Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more.

 
Subscribe Now
 
Sign in to your account.
25
Nov
2016

Lilly’s Alzheimer’s Strikeout, Juno’s Double Whammy, and Sanofi Yanks Bladder Cancer Drug

/
Luke Timmerman
/
0
/
All
25 Nov 2016

Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more.

 
Subscribe Now
 
Sign in to your account.
21
Nov
2016

A Gift for Your Board, Clients, or Kids: Signed Copies of “Hood”

/
Luke Timmerman
/
0
/
All, Genomics
21 Nov 2016

Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more.

 
Subscribe Now
 
Sign in to your account.
18
Nov
2016

Obamacare Overhaul, Gutsy Theranos Whistleblower Revealed, & Painkiller Confusion

/
Luke Timmerman
/
0
/
All
18 Nov 2016

Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more.

 
Subscribe Now
 
Sign in to your account.
18
Nov
2016

Sounding The Alarm Over Brexit, UK Biotech Struggles to Cope With Isolationism

/
Steven Dickman
/
0
/
All, Politics
18 Nov 2016

Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more.

 
Subscribe Now
 
Sign in to your account.
14
Nov
2016

Dealing With Megawatt Scientists: Big Talkers, Control Freaks, and Demigods

/
Luke Timmerman
/
0
/
All
14 Nov 2016

Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more.

 
Subscribe Now
 
Sign in to your account.
11
Nov
2016

Biotech Stocks Soar, Trump Healthcare Speculation Roars, & Valeant Bumbles

/
Luke Timmerman
/
2
/
All
11 Nov 2016

Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more.

 
Subscribe Now
 
Sign in to your account.
10
Nov
2016

Time to Take Out the Crystal Ball to Figure Out What Trump Will Do on Healthcare

/
Leora Schiff
/
0
/
All, Politics
10 Nov 2016

Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more.

 
Subscribe Now
 
Sign in to your account.
‹ Previous 1 … 65 66 67 68 69 … 79 Next ›

Get In-depth Biotech Coverage with Timmerman Report.

Individual Subscription

Group Subscription

Or: Sign in to your account

Your account

Sign in

What Readers Are Saying

testimonial
testimonial
testimonial

View More Testimonials ➛

Twitter

Tweets by ldtimmerman Follow @ldtimmerman
© Copyright 2025, TimmermanReport.com
Privacy Policy | Terms of Use
Custom WordPress site by: Perception Builder